Coe Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Coe Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,708	Closed	-$756K	–	85
2016 Q3	$756K	Hold	3,708	–	–	0.24%	134
2016 Q2	$534K	Sell	3,708 -2,000	-35%	-$268K	0.18%	151
2016 Q1	$820K	Buy	5,708 +2,500	+78%	+$353K	0.26%	108
2015 Q4	$689K	Hold	3,208	–	–	0.27%	113
2015 Q3	$519K	Buy	3,208 +375	+13%	+$81.1K	0.19%	136
2015 Q2	$731K	Buy	2,833 +1,000	+55%	+$239K	0.27%	125
2015 Q1	$412K	Hold	1,833	–	–	0.17%	160
2014 Q4	$352K	Sell	1,833 -450	-20%	-$96.3K	0.11%	195
2014 Q3	$490K	Buy	2,283 +500	+28%	+$97.2K	0.18%	147
2014 Q2	$464K	Buy	1,783 +783	+78%	+$171K	0.17%	152
2014 Q1	$218K	Sell	1,000 -2,072	-67%	-$307K	0.06%	222
2013 Q4	$375K	Buy	+3,072	New	+$411K	0.13%	166

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

JMPWA

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Coe Capital Management's AXDX Position: Q4 2016 in Review

Coe Capital Management sold out of Accelerate Diagnostics (AXDX) in Q4 2016, closing a stake of 3,708 shares — an estimated $756K sold.

Coe Capital Management first reported a position in AXDX in Q4 2013 and held it in 12 quarters. The position peaked at $820K in Q1 2016. 109 funds tracked by Wall St. Rank hold AXDX as of Q4 2016.

Coe Capital Management reported no remaining Accelerate Diagnostics position as of Q4 2016 after selling out during the quarter.
Coe Capital Management sold 3,708 Accelerate Diagnostics shares in Q4 2016, an estimated $756K.
Coe Capital Management first reported a position in Accelerate Diagnostics in Q4 2013 and held it in 12 quarters.
Coe Capital Management's Accelerate Diagnostics position peaked at $820K in Q1 2016.
109 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2016.

Based on Coe Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.